Imugene presenting all three immuno-oncology programs at AACR Annual Meeting

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive Investors about news the company’s KEY-Vaxx and B-Vaxx cancer vaccine programs will be presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Lead candidate HER-Vaxx was tapped for inclusion last week, meaning that now all three of the clinical stage immuno-oncology company’s programs will be featured.

source

This page is served from the static folder and not from the database.